About ImmunoBiology Ltd

About company

ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary technologies. ImmBio is developing next-generation vaccines against serious infectious disease targets, utilising its proprietary technology platforms to directly induce immunity via dendritic cells. ImmBio's lead programme is a vaccine against invasive pneumococcal disease, PnuBioVax™, that has recently progressed into full clinical development with the successful completion of a Phase I Clinical trial.